News Novartis drug flunks phase 3 test in giant cell arteritis Novartis hopes of bringing Cosentyx to patients with giant cell arteritis seem to be over after the drug missed all the endpoints in a phase 3 trial.
News ASCO 25: Roche places Itovebi marker in breast cancer Roche's Itovebi has become the first PI3K inhibitor to extend survival in HR-positive, HER2-negative breast cancer with a PIK3CA mutation.
News PTC's Huntington study was positive. Why did its stock fall? In a potentially pivotal trial, PTC Therapeutics' therapy for Huntington's disease met its primary endpoint, but there are questions about the data.
News Novartis grabs kidney drug developer Regulus in $1.7bn deal Novartis has grown in renal diseases once again with a $1.7bn deal to buy Regulus and its autosomal dominant polycystic kidney disease (ADPKD) drug.
Market Access Reuters Europe 2025: Using value propositions to improve acc... In a Reuters Pharma Europe 2025 fireside chat, NICE Advice Director Brad Grove spoke with Novartis's Matic Meglic about novel pharma payment models.
News Novartis plans $23bn manufacturing, R&D spend in US Novartis has announced a massive investment in manufacturing and R&D facilities in the US so it can make "100% of its key medicines" there.
News Summit climbs on rumour of $15bn AstraZeneca interest Is AstraZeneca about to join the ranks of pharma companies spending big bucks on PD(L)-1xVEGF bispecific antibodies for cancer?
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face